查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
特發性肺纖維化市場－全球與區域分析、區域分析與預測（2025-2035）
市場調查報告書
商品編碼
1818892

特發性肺纖維化市場－全球與區域分析、區域分析與預測（2025-2035）

Idiopathic Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

全球特發性肺纖維化市場 - 分析與預測（2025-2035）

特發性肺纖維化 (IPF) 是進行性性肺部疾病，其特徵是肺組織逐漸瘢痕化（纖維化），損害肺部正常運作的能力。

「特發性」是指確切病因尚不清楚，但據信是由遺傳和環境因素共同作用所致。在特發性肺纖維化（IPF）中，纖維組織的形成會導致肺部僵硬，從而引發呼吸困難，尤其是在運動時。

隨著病情進展，瘢痕形成範圍會擴大，進一步限制血液中的氧氣輸送。特發性肺纖維化 (IPF) 的症狀包括呼吸急促、持續乾咳、疲勞和不明原因的體重減輕。雖然病情進展因人而異，但目前尚無治療方法，治療方法重點在於控制症狀和減緩病情進展。早期診斷和醫療介入對於改善 IPF 患者的生活品質和延長生存期至關重要。

特發性肺纖維化 (IPF) 的高盛行率是推動治療方法和治療方案研發的關鍵驅動力。該疾病主要影響老年人，由於人口老化和公眾對該疾病的認知提高，全球確診病例正在增加。不斷成長的患者群體對有效治療方法和新型治療方案的需求很大。隨著越來越多的患者被診斷出患有特發性肺纖維化 (IPF)，製藥公司和醫療保健提供者積極應對與這種進行性且通常致命的疾病相關的未滿足醫療需求。盛行率越高，投資研發以提高生存率和生活品質就越重要。

活性化研發活動是推動 IPF 治療進步的關鍵驅動力之一。研究人員正在努力了解導致 IPF 的遺傳、分子和環境因素，以幫助開發更有針對性和更有效的治療方法。隨著我們對 IPF 的了解不斷加深，重點正轉向精準醫療，這可以根據每個人的基因特徵來客製化治療方案。研發工作也正致力於改善藥物輸送系統、最佳化現有治療方法以及探索可以解決纖維化根本原因的新型藥物。這種對研發的加強重視加速了創新，從而發現了候選藥物，並使得能夠開發出為患者帶來更好結果的治療方法。活性化研發也促進了跨產業合作，使研究人員、製藥公司和醫療保健組織能夠應對 IPF 帶來的挑戰。

然而，儘管成長前景光明，特發性肺纖維化市場仍面臨挑戰。一個主要障礙是有效治療方案有限。雖然有幾種核准的抗纖維化療法，如Pirfenidone和尼達尼布，但這些治療方法主要旨在減緩疾病進展，而不是逆轉它。此外，這些治療方法並非對所有患者都有效，目前的選擇只針對症狀，而不是 IPF 的根本原因。 IPF 目前尚無治癒治療方法，缺乏替代治療方法給患者和醫療保健系統帶來了沉重的負擔。治療方法有限，再加上大多數現有治療方法只能減緩而不是預防疾病進展，限制了疾病的整體管理。這是市場面臨的一個主要限制因素，因為市場迫切需要更有效的疾病修正治療。

全球特發性肺纖維化市場競爭激烈，許多主要企業推動技術創新和市場成長。霍夫曼羅氏有限公司、Pliant Therapeutics, Inc.、百時美施貴寶、Vicore Pharma AB 和 Pliant Therapeutics, Inc. 等公司處於開發和商業化特發性肺纖維化 (IPF) 治療方案的前沿。這些公司正在大力投資開發下一代治療方法，包括標靶治療治療、生物製劑和創新藥物傳遞系統，以加強其在特發性肺纖維化 (IPF) 治療的市場地位。他們正在改進目前的抗纖維化療法，擴大肺移植選擇，並探索可能減緩疾病進展和逆轉肺損傷的新方法。此外，這些公司正在進行大規模臨床試驗，以評估新治療方法的有效性、安全性和長期益處，努力更好地了解 IPF 的潛在機制並提供新的、更有效的治療方法。透過與學術和研究機構建立策略夥伴關係和合作，我們旨在加速開發突破性治療方法，改善患者的治療效果，並為受這種危及生命的疾病影響的人們帶來希望。

市場區隔

細分1：按地區

  • 北美洲
  • 歐洲
  • 亞太地區

鑑於目前可用的治療方法有限，製藥公司擁有重大機會來開發針對特發性肺纖維化（IPF）根本病因而非僅控制其症狀的新型治療方法。基因療法、幹細胞療法、個人化醫療和先進生技藥品等創新療法有望提供更具針對性和有效性的治療方案。這些治療方法專注於在基因或分子層面逆轉或阻止纖維化過程，有望顯著改善患者的預後和生活品質。隨著我們對特發性肺纖維化（IPF）遺傳和分子機制的理解不斷加深，發現能夠改變IPF病程的突破性治療方法，將帶來寶貴的市場機會。

目錄

執行摘要

第 1 章全球特發性肺纖維化市場：產業分析

  • 市場概況與生態系統
  • 流行病學分析
  • 主要市場趨勢
    • 影響分析
  • 監管狀況
  • 管道分析
  • 市場動態
    • 概述
    • 市場促進因素
    • 市場限制
    • 市場機遇

2. 全球特發性肺纖維化市場（按地區）及價值，2023-2035年

  • 北美洲
    • 市場動態
    • 市場規模及預測
    • 2023-2035年北美特發性肺纖維化市場（百萬美元）
  • 歐洲
    • 市場動態
    • 市場規模及預測
    • 歐洲特發性肺纖維化市場（百萬美元）按國家分類，2023-2035 年
  • 亞太地區
    • 市場動態
    • 市場規模及預測
    • 2023-2035年亞太地區特發性肺纖維化市場（百萬美元）

第3章：競爭格局與公司概況

  • 競爭格局
  • 公司簡介
    • Hoffmann-La Roche Ltd.
    • Boehringer Ingelheim Pharma GmbH & Co. KG
    • Pliant Therapeutics, Inc.
    • Vicore Pharma AB
    • Kadmon Corporation, LLCs
    • Bristol-Myers Squibb
    • PureTech
    • Nitto Denko Corporation
    • Bridge Biotherapeutics, Inc.
    • Galecto Biotech
    • Tvardi Therapeutics, Incorporated.
    • Galecto Biotech
    • 其他

第4章調查方法

Product Code: BHL3271SA

Global Idiopathic Pulmonary Fibrosis Market, Analysis and Forecast: 2025-2035

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by the gradual scarring (fibrosis) of lung tissue, which impairs the ability of the lungs to function properly. The term "idiopathic" means that the exact cause of the disease is unknown, though it is believed to result from a combination of genetic and environmental factors. In IPF, the lungs become stiff due to the formation of fibrous tissue, leading to difficulty in breathing, especially during physical activity.

As the disease advances, the scarring becomes more extensive, further limiting the oxygen supply to the bloodstream. Symptoms of IPF include shortness of breath, a persistent dry cough, fatigue, and unexplained weight loss. The progression of the disease varies among individuals, but there is currently no cure, and treatments focus on managing symptoms and slowing the disease's progression. Early diagnosis and medical intervention are crucial to improving the quality of life and extending survival in patients with IPF.

The high prevalence of IPF has become a significant driver for the development of therapies and treatment solutions. The disease primarily affects older adults, with an increasing number of diagnosed cases globally due to an aging population and improved awareness of the condition. This growing patient population creates a substantial demand for effective treatments and new therapeutic options. As more people are diagnosed with IPF, pharmaceutical companies and healthcare providers are motivated to address the unmet medical needs associated with this progressive and often fatal disease. The higher the prevalence, the more essential it becomes to invest in research and the development of therapies that can improve survival rates and quality of life.

Increasing R&D activities are one of the key drivers for the advancement of IPF treatments. Researchers are working to uncover the genetic, molecular, and environmental factors that contribute to the disease, helping to develop more targeted and effective therapies. As the understanding of IPF deepens, the focus is shifting toward precision medicine, where treatments can be tailored to individual genetic profiles. R&D efforts are also being directed at improving drug delivery systems, optimizing existing therapies, and exploring new classes of drugs that can address the underlying causes of fibrosis. This heightened focus on R&D accelerates innovation, leads to the discovery of new drug candidates, and enables the development of treatment regimens that can provide better results for patients. Increased R&D also promotes collaboration across industries, bringing together researchers, pharmaceutical companies, and healthcare institutions to tackle the challenges posed by IPF.

However, despite the promising growth prospects, challenges remain in the idiopathic pulmonary fibrosis market. A major hurdle is the limited number of effective treatment options available. While there are a few approved antifibrotic therapies, such as pirfenidone and nintedanib, these treatments primarily aim to slow the progression of the disease rather than reverse it. Additionally, these therapies may not be effective for all patients, and the current options only address the symptoms, not the root cause of IPF. There is no known cure for IPF, and the lack of alternative treatment options places a considerable burden on patients and healthcare systems. The limited availability of therapies, coupled with the fact that most current treatments can only delay disease progression rather than prevent it, restricts the overall management of the disease. This is a major restraint in the market as there is a critical need for more effective, disease-modifying therapies.

The global idiopathic pulmonary fibrosis market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., Bristol-Myers Squibb, Vicore Pharma AB, and Pliant Therapeutics, Inc., are at the forefront of developing and commercializing treatment options for idiopathic pulmonary fibrosis. These companies are investing significantly in the development of next-generation therapies, including targeted treatments, biologic therapies, and innovative drug delivery systems to strengthen their market position in the treatment of idiopathic pulmonary fibrosis (IPF). By focusing on improving current antifibrotic therapies, enhancing lung transplantation options, and exploring novel approaches aim to slow disease progression and potentially reverse lung damage. Additionally, these companies are conducting extensive clinical trials to evaluate the efficacy, safety, and long-term benefits of emerging therapies, striving to better understand the underlying mechanisms of IPF and offer new, more effective treatment alternatives. Through strategic partnerships and collaboration with academic institutions and research organizations, they aim to accelerate the development of breakthrough therapies that can improve patient outcomes and provide hope for individuals affected by this life-threatening condition.

Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

With limited treatment options currently available, there is a substantial opportunity for pharmaceutical companies to develop novel therapies that address the underlying causes of IPF, rather than just managing its symptoms. Innovative therapeutic approaches such as gene therapy, stem cell therapy, personalized medicine, and advanced biologics have the potential to offer more targeted and effective treatments. By focusing on reversing or halting the fibrosis process at the genetic or molecular level, these therapies could significantly improve patient outcomes and quality of life. As researchers continue to uncover the genetic and molecular mechanisms of IPF, the potential for discovering breakthrough treatments that could alter the course of the disease becomes a valuable market opportunity.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Idiopathic Pulmonary Fibrosis Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Overview
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Idiopathic Pulmonary Fibrosis Market (by Region), Value ($Million), 2023-2035

  • 2.1 North America
    • 2.1.1 Market Dynamics
    • 2.1.2 Market Sizing and Forecast
    • 2.1.3 North America Idiopathic Pulmonary Fibrosis Market, by Country ($Million), 2023-2035
      • 2.1.3.1 U.S.
  • 2.2 Europe
    • 2.2.1 Market Dynamics
    • 2.2.2 Market Sizing and Forecast
    • 2.2.3 Europe Idiopathic Pulmonary Fibrosis Market, by Country ($Million), 2023-2035
      • 2.2.3.1 U.K.
      • 2.2.3.2 France
      • 2.2.3.3 Germany
      • 2.2.3.4 Italy
      • 2.2.3.5 Spain
  • 2.3 Asia-Pacific
    • 2.3.1 Market Dynamics
    • 2.3.2 Market Sizing and Forecast
    • 2.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, by Country ($Million), 2023-2035
      • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Partnership, Alliances and Business Expansion
    • 3.1.3 New Offerings
    • 3.1.4 Regulatory Activities
    • 3.1.5 Funding Activities
  • 3.2 Company Profiles
    • 3.2.1 Hoffmann-La Roche Ltd.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Boehringer Ingelheim Pharma GmbH & Co. KG
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Pliant Therapeutics, Inc.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Vicore Pharma AB
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Kadmon Corporation, LLCs
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Bristol-Myers Squibb
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 PureTech
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Nitto Denko Corporation
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Bridge Biotherapeutics, Inc.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Galecto Biotech
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 Tvardi Therapeutics, Incorporated.
      • 3.2.11.1 Overview
      • 3.2.11.2 Top Products / Product Portfolio
      • 3.2.11.3 Top Competitors
      • 3.2.11.4 Target Customers/End-Users
      • 3.2.11.5 Key Personnel
      • 3.2.11.6 Analyst View
    • 3.2.12 Galecto Biotech
      • 3.2.12.1 Overview
      • 3.2.12.2 Top Products / Product Portfolio
      • 3.2.12.3 Top Competitors
      • 3.2.12.4 Target Customers/End-Users
      • 3.2.12.5 Key Personnel
      • 3.2.12.6 Analyst View
    • 3.2.13 Others

4. Research Methodology

List of Figures

  • Figure: Global Idiopathic Pulmonary Fibrosis Market Coverage
  • Figure: Global Idiopathic Pulmonary Fibrosis Market Key Trends, Impact Analysis, 2023-2035

List of Tables

  • Table: Global Idiopathic Pulmonary Fibrosis Market Dynamics, Impact Analysis
  • Table: Global Idiopathic Pulmonary Fibrosis Market (by Region), $Million, 2023-2035